Trial reportAnatolian journal of cardiology2025
Effects of Dapagliflozin on Left Atrial Ejection Force in Heart Failure with Preserved Ejection Fraction: DAPA-Left Atrial Ejection Force Trial.
Trial report in Anatolian journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft atrial ejection force (LAEF) represents the force exerted by the left atrium (LA) to push blood into the left ventricle (LV) at the end of diastole. It is calculated as LAEF = 1/3 × mitral orifice area × (peak A velocity)2.
methodsThe primary endpoint was to assess changes in LAEF after 6 months of sodium-glucose co-transporter-2 inhibitor (SGLT-2 inhibitor) therapy in patients with heart failure with preserved ejection fraction (HFpEF). Secondary endpoints include changes in diastolic function, LV global longitudinal strain (LV-GLS), and LA strain parameters.
resultsIn this single-center, prospective, randomized open-label study, 100 HFpEF patients were divided into 2 groups (n = 50 each). The study group received Dapagliflozin 10 mg daily along with guideline-directed medical therapy (GDMT) for 6 months, while the control group received only GDMT. The study group showed a significant reduction in LAEF (143.74 ± 10.33 to 134.4 ± 8.82; P < .001), LV-GLS improvement (-15.9 ± 4.13 to -17.1 ± 3.53; P < .001), and enhanced LA strain parameters (LA reservoir strain: 28.74 ± 9.31% to 36.39 ± 12.3%; LA contractile strain: -12.8 ± 5.41 to -17.89 ± 6.85; LA conduit strain: -15.97 ± 5.49 to -22.5 ± 8.25; all P < .001). Additionally, left ventricular mass index (199.9 ± 21.17 to 186.24 ± 16.77; P < .001) and left atrial volume index (36.17-32.21 mL/m2; P < .001) significantly decreased.
conclusionDapagliflozin significantly reduces LAEF while improving LA strain and LV-GLS, reinforcing its role in LA and LV reverse remodeling in patients with HFpEF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.